Menveo Vaccine: A Meningococcal meningitis vaccine
Menveo vaccine is used to prevent the Meningococcal Meningitis disease. It is vaccine by GSK pharma. It is Killed Meningococcal vaccine.
Menveo Menongococcal Meningitis Vaccine is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
This is Diphtheria CRM197 Conjugate Vaccine.
Menveo Menongococcal Meningitis Vaccine is approved for use in persons aged 2 months through 55 years. Menveo Menongococcal Meningitis Vaccine does not prevent N. meningitidis serogroup B infections.
This vaccine is available in 0.5 ml dosages.
How is Menveo Meningococcal Meningitis vaccine available?
Menveo Menongococcal Meningitis Vaccine is available as injection liquid form. MenA lyophilized conjugate component and MenCYW-135 components are available in 2 separate vials. It is available as 0.5 ml dose. It is available in single dose form. It is packed in opaque box to protect from sunlight. MENVEO is supplied in 2 vials that must be combined prior to administration: reconstitute the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component immediately before administration.
How is Menveo Meningococcal Meningitis vaccine stored?
Menveo Menongococcal Meningitis Vaccine is stored at 2-8 degree Celsius. The temperature range should be maintained with the help of cold chain. The temperature range should be maintained at all levels of transport and storage. The vaccine should not be frozen. If the vaccine is frozen accidentally it should be discarded and not used for the injection.
How is Menveo Meningococcal Meningitis vaccine given?
Menveo Menongococcal Meningitis Vaccine is reconstituted, the MenA lyophilized conjugate vaccine component is mixed with the MenCYW-135 liquid conjugate vaccine component immediately before administration. Menveo Menongococcal Meningitis Vaccine is given as injection on the antero lateral aspect of thigh in children with needle as intramuscular route. All the safe injection precautions should be followed while giving injection. The disposables should be discarded as per biomedical waste management protocols. The vaccine that has passed expiry should be discarded as per biomedical waste management protocol rules.
For those who have bleeding disorder this vaccine can be administered subcutaneously and firm pressure is given after the vaccination. The vaccination should be preferably planned after getting the dose of clotting factor in haemophilliacs.
At what age Menveo Meningococcal Meningitis vaccine is given?
Primary Immunization
· In children initiating vaccination at 2 months of age, Menveo Menongococcal Meningitis Vaccine is to be administered as a 4-dose series at 2, 4, 6, and 12 months of age.
· In children initiating vaccination at 7 months through 23 months of age, MENVEO is to be administered as a 2-dose series with the second dose administered in the second year of life and at least 3 months after the first dose.
· In individuals aged 2 through 55 years MENVEO is to be administered as a single dose.
Boosters
· A single booster dose of MENVEO may be administered to individuals aged 15 through 55 years who are at continued risk for meningococcal disease if at least 4 years have elapsed since a prior dose of a meningococcal (serogroups A, C, Y, W-135) conjugate vaccine.
How does Menveo Meningococcal Meningitis vaccine works?
Menveo Menongococcal Meningitis Vaccine is a killed vaccine. It is used to prevent the infection and inflammation caused by Neisseria meningitidis serogroups A, C, Y, and W-135. This Neisseria meningitidis is also called as meningococcus because it infects the meninges the thin covering of the brain and causes disease meningitis which is life threatening in many cases even after treatment. This vaccination is active form of immunization and when it is injected in adequate doses to someone the immunity of the host recognizes the antigens in this vaccine as foreign antigens and form immune response against these antigens. When given as per schedule in adequate doses as suggested body also develops long term immunity in the process. When the real infection occurs the body fights the infection more vigorously and the disease is prevented. Thus this is active form of immunization.
Safety with other vaccine:
This Menongococcal Meningitis Vaccine is safe with most other medicine and no drug interactions were noted. The other vaccine or other drug should not be mixed in same syringe as this vaccine.
Like other inactivated vaccines Menveo Menongococcal Meningitis Vaccine is considered as safe in pregnant and lactating woman, but the risk benefit ratio should be evaluated by the caregiver.
Concomitant administration of typhoid, tetanus and yellow fever vaccine is safe with Menveo Menongococcal Meningitis Vaccine.
This vaccine is also safe when given with diphtheria, pertussis, HiB and pneumococcal vaccines.
What are side effects of This Meningococcal Meningitis vaccine?
This Menongococcal Meningitis Vaccine causes side effect that are generally milder and can be managed at home and does not need hospital admission:
· Fever is common side effect after the vaccination. It usually subsides in 1-3 days and can be managed very easily at home with medicine like paracetamol and sponging.
· Swelling and pain occurs at injection site may last for 1-3 days can be managed with paracetamol and local cold compression.
· Diarhea and loss of appetite can occur after vaccination and can be managed by oral rehydrating solution.
· Nausea and vomiting may occur after the vaccination and it can be managed by oral syp ondansetron and oral rehydrating solution.
· Muscular pain and joint pain.
· Headache and fatigue.
· Anaphylaxis and allergy is extremely rare side effect of the vaccine. Like other vaccines the vaccine should be administered at center where necessary personnel and drugs and equipments are available to manage if any reaction occurs.